Global Microbiome Therapeutics Market
A microbiome is genetic material of all microbes such as bacteria, virus, fungi and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For instance, about a third bacteria in the gut are Bacteroides species, whereas Streptococcus species are dominant about oral health. Microbiomes plays the significant role in human health and disease conditions.
Increase in evidence about the direct relationship of the microbiome in treating lifestyle diseases, autoimmune diseases such as Crohn’s, inflammatory bowel disease (IBS) conditions are fuelling the growth of the market. Currently, very few drugs are available in the market to treat these disease conditions. Furthermore, microbiome therapeutics are safer than conventional treatments as they are already present in human body. Microbiome therapeutics didn’t possess any side-effects, unlike conventional drugs these factors will have the positive impact on the growth of the market. However, lack of substantial clinical evidence about the microbiome benefits on human health and regulatory barriers might hamper the growth of the market over the forecast period.
Global Mircobiome Therapeutics Market has been segmented based on Product Type, and Disease Indication
Based on the product type, Global Mircobiome Therapeutics Market has been segmented into the following:
- Synbiotics (Combination of Prebiotics and Probiotics)
Based on Disease Indication, Global Mircobiome Therapeutics Market has been segmented into the following:
- Digestive related disorders
- o Crohn’s disease
- o Inflammatory Bowel Disease (IBD)
- o Irritable Bowel Syndrome (IBS)
- o Others
- Metabolic Disorders
- o Obesity
- o Diabetes
- o Others
- Respiratory Infections
- Immune System
- Oral Diseases
- Skin Infections
Global Mircobiome Therapeutics Market is still nascent stage, very products in the market are currently approved to treat various therapeutic conditions. Start-ups are very active in the microbiome therapeutics market in terms of product launches, research and development activities. However, bigger players in microbiome therapeutics market are focused to provide funding, collaborating and acquiring smaller players to promote the research activities. Furthermore, Venture Capitalists and Government Organisations are actively involved in funding and encouraging the research activities. The launch of microbiome therapeutics products in the market expected to fuel the demand of the market over the forecast. For instance, in May 2014, Pfizer entered an agreement with Second Genome to conduct research on obesity and metabolic disorders. In April 2016, the company also raised US$ 42.6 Mn in Series B funding led by Pfizer Venture Investments and Roche Venture Fund. The funding amount will be used to conduct the clinical investigation on SGM-109, a small molecule inhibitor of a microbiome mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US$ 40 Mn in Series-B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for inborn errors of metabolism of Urea Cycle Disorder and Phenylketonuria conditions.
Geographically market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Europe accounted for the larger share in terms of research and development followed by North America. Active involvement of government organisation owing to encourage the research on microbiome in European countries. For instance, MetaGenoPolis (MGP) program that was financed by French Initiative “Investissements d’Avenir” to understand the human microbiome impact on human health. In June 2014, MyNewGut project received funding from the European Union, to develop dietary interventions that have the impact on controlling obesity, diabetes, and cardiovascular disease conditions. In Asia-Pacific region, research on microbiome therapeutics is also actively carried out by research institutes through government funding programs. In 2010, Korean Microbiome Diversity Using Korean Twin Cohort Project was funded by National Research Foundation of Korea. The aim of the project is to identify target microbiome and genes that are associated with human diseases.
Global Microbiome Therapeutics Market dominated by key players such as Johnson & Johnson, Pfizer Inc., AB biotics, Enterome, Seres Therapeutics, Vedanta Biosciences, Eligo Bioscience, 4D Pharma plc, Synlogic, TargEDys, Second Genome, LNC research & development, Takeda Pharmaceutical Company Ltd, PROBI, and Ritter Pharmaceuticals.
- In July 2016, Series Therapeutics started a clinical trial on its synthetically designed microbiome drug SER-262, to treat Clostridium difficile infection conditions. The study is currently enrolling patients from 22 locations in the U.S.
- In February 2015, 4D Pharma plc, U.K. based company, acquired Tucana that involved in development of microbiome therapeutics product to treat Irritable Bowel Syndrome (IBS) conditions
- In January 2016, Takeda Pharmaceuticals Ltd and Enterome entered strategic drug discovery collaboration to conduct research and development on novel therapeutics that targets microbiome that plays crucial roles in multiple gastrointestinal disease conditions
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario